Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noisy Rebels
2022-502664-21-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in multiple sclerosis (MS) comparing Rituximab arm with Ocrelizumab arm (2 arms). Primary endpoint: No new or enlarged T2 lesions on brain MRI between month 6 and month 24. Planned start Mar 2023; status: authorised.
02
Drugs
rituximabocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-502664-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502664-21-00.